Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model
- PMID: 31052254
- PMCID: PMC6539990
- DOI: 10.3390/molecules24091694
Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model
"V体育官网入口" Abstract
The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1 mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61. 5, 184. 5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) of the maximum recommended human maintenance dose of CBD in EPIDIOLEX® (20 mg/kg). In the acute study, significant increases in liver-to-body weight (LBW) ratios, plasma ALT, AST, and total bilirubin were observed for the 2460 mg/kg dose VSports手机版. In the sub-acute study, 75% of mice gavaged with 615 mg/kg developed a moribund condition between days three and four. As in the acute phase, 615 mg/kg CBD increased LBW ratios, ALT, AST, and total bilirubin. Hepatotoxicity gene expression arrays revealed that CBD differentially regulated more than 50 genes, many of which were linked to oxidative stress responses, lipid metabolism pathways and drug metabolizing enzymes. In conclusion, CBD exhibited clear signs of hepatotoxicity, possibly of a cholestatic nature. The involvement of numerous pathways associated with lipid and xenobiotic metabolism raises serious concerns about potential drug interactions as well as the safety of CBD. .
Keywords: cannabidiol; hepatotoxicity; liver injury; natural products; phytochemical. V体育安卓版.
Conflict of interest statement
Quick serves as a scientific consultant for Allergen. The other authors have no conflicts of interest to disclose V体育ios版.
Figures
References
-
- Devinsky O., Cross J.H., Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N. Eng. J. Med. 2017;377:699–700. doi: 10.1056/NEJMoa1611618. - "V体育2025版" DOI - PubMed
-
- Thiele E.A., Marsh E.D., French J.A., Mazurkiewicz-Beldzinska M., Benbadis S.R., Joshi C., Lyons P.D., Taylor A., Roberts C., Sommerville K., et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–1096. doi: 10.1016/S0140-6736(18)30136-3. - DOI - PubMed
-
- Crippa J.A., Guimaraes F.S., Campos A.C., Zuardi A.W. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front. Immunol. 2018;9:2009. doi: 10.3389/fimmu.2018.02009. - VSports在线直播 - DOI - PMC - PubMed
-
- Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad Sci. USA. 1998;95:8268–8273. doi: 10.1073/pnas.95.14.8268. - V体育官网入口 - DOI - PMC - PubMed
MeSH terms
- "V体育官网入口" Actions
- Actions (VSports)
- "V体育ios版" Actions
- V体育平台登录 - Actions
- Actions (VSports注册入口)
- VSports在线直播 - Actions
Substances
- Actions (V体育安卓版)
Grants and funding
LinkOut - more resources
Full Text Sources
VSports app下载 - Medical
Molecular Biology Databases
Research Materials (VSports注册入口)
